Randomized Phase 11 Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatis Triple-Negative Breast Cancer

Randomized Phase 11 Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatis Triple-Negative Breast Cancer

Bibliographic Details
Main Authors: Baselga, J., Gomez, P., Greil, R., Braga, S., Climent, M., Wardley, A., Kaufman, B., Stemmer, S., Pego, A., Chan, Arlene, Goeminne, J., Graas, M., Kennedy, J., Ciruelos, E.M., Schneeweiss, A., Zubel, A., Groos, J., Melezinkova, H., Awada, A.
Format: Journal Article
Published: American Society of Clinical Oncology 2013
Online Access:http://hdl.handle.net/20.500.11937/8601

Internet

http://hdl.handle.net/20.500.11937/8601

Similar Items